G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating, because that familiar routine of meetings and deadlines and what-not has now returned. You knew this moment would come, yes? So please join as we hoist another cup of stimulation in hopes of coping with the onslaught. Our flavor today, by the way, is a delightful mix of coconut, caramel, and mocha. Yum. Meanwhile, here are some tidbits to provide another sort of stimulation. Hope you have a smashing day and please do keep in touch …

Brexit may affect the cost of drugs and hit U.K. pharmaceutical investment, a government committee head  warns, the BBC reports. Several large drug makers also expressed concern about disruption to supply chains, clinical trials, and recruiting if the U.K. does not withdraw in an orderly manner from the European Union, The Telegraph says. Meanwhile, a U.S.-based life-sciences investment fund, with backing from GlaxoSmithKline (GSK), plans to invest up to $1 billion to create a large biotech company in the U.K., according to The Financial Times.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I doubt the veracity of the Irish tale. If there were truly an inhaled version of Viagra Pfizer would have patented it long ago and would be a blockbuster today for the flagging libido set unwilling to wait 45 minutes for the pill to kick in.

  • One wonders if there have been any reports of the side effects of the ‘blue pill’ having occurred as well, such as loss of vision? “We shall see…” so to speak.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.